Skip to main content
. 2021 Jun 12;98:107874. doi: 10.1016/j.intimp.2021.107874

Table 3.

Concomitant therapy administered and adverse events reported.

Overall patients (n = 92) Control Group (n = 44) Blood Ozonization Group (n = 48) P
Concomitant therapy
  • •

    Antiretroviral therapy

 87 (94.6%) 42 (95.5%) 45 (93.8%) 1.000
  • •

    Hydroxychloroquine

 92 (100%) 44 (100%) 48 (100%) 1.000
  • •

    Systemic steroids

 56 (60.9%) 32 (72.7%) 24 (50.0%) 0.044
  • •

    LMWE

 68 (73.9%) 31 (70.5%) 37 (77.1%) 0.627
  • •

    Antibiotic therapy

 43 (46.7%) 20 (45.5%) 23 (47.9%) 0.978
  • •

    Tocilizumab

 5 (5.4%) 1 (2.3%) 4 (8.3%) 0.412
Adverse events
  • •

    Overall Adverse events

 15 (16.3%) 7 (16.3%) 8 (16.7%) 1.000
  • •

    Diarrhoea

 4 (4.4%) 3 (6.8%) 1 (2.1%) 0.548
  • •

    QT interval prolongation

 7 (7.6%) 3 (6.8%) 4 (8.3%) 1.000
  • •

    Increase liver enzyme

 3 (3.3%) 0 (0.0%) 3 (6.3%) 0.272
  • •

    Antiretroviral discontinuation

 10 (10.9%) 5 (11.4%) 5 (10.4%) 1.000
  • •

    Hydroxychloroquine discontinuation

 6 (6.5%) 3 (6.8%) 3 (6.3%) 1.000